6610 fundamentals
Key facts
Market capitalization—
Founded—
CEO—
Website—
About
TWi Biotechnology, Inc. operates as a clinical stage biopharmaceutical company. It engages in the research and development of repositioned drugs for unmet medical needs, especially in rare diseases associated with innate immunity. The company was founded by Chih Ming Chen on July 16, 2010 and is headquartered in Taipei, Taiwan.
Valuation
Fundamental metrics to determine fair value of the stock
Growth and Profitability
Company’s recent performance and margins
Dividends
Dividend yield, history and sustainability
No dividends
6610 has never paid dividends and has no current plans to do so.
Financial health
Financial position and solvency of the company